Sökning: id:"swepub:oai:lup.lub.lu.se:6c3f6be6-eecc-466f-b260-a9a997613e8c" >
Inhibitors in haemo...
Inhibitors in haemophilia A and B : Management of bleeds, inhibitor eradication, and strategies for difficult-to-treat patients
-
- Ljung, Rolf (författare)
- Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Pediatrisk hematologi,Forskargrupper vid Lunds universitet,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Paediatric Haematology Research Unit,Lund University Research Groups,Skåne University Hospital
-
- Auerswald, Guenter (författare)
- Klinikum Bremen-Mitte
-
- Benson, Gary (författare)
- Belfast City Hospital
-
visa fler...
-
- Dolan, Gerry (författare)
- St Thomas' Hospital
-
- Duffy, Anne (författare)
- Irish Haemophilia Society
-
- Hermans, Cedric (författare)
- Saint-Luc University Hospital
-
- Jiménez-Yuste, Victor (författare)
- Autonomous University of Madrid
-
- Lambert, Thierry (författare)
- Bicêtre Hospital
-
- Morfini, Massimo (författare)
- Italian Association of Haemophilia Centres
-
- Zupančić-Šalek, Silva (författare)
- University of Osijek,University of Zagreb
-
- Santagostino, Elena (författare)
- Maggiore Hospital Policlinico
-
visa färre...
-
(creator_code:org_t)
- 2018-12-06
- 2019
- Engelska.
-
Ingår i: European Journal of Haematology. - : Wiley. - 1600-0609 .- 0902-4441. ; 102:2, s. 111-122
- Relaterad länk:
-
http://dx.doi.org/10...
-
visa fler...
-
https://onlinelibrar...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The standard therapy for patients with haemophilia is prophylactic treatment with replacement factor VIII (FVIII) or factor IX (FIX). Patients who develop inhibitors against FVIII/FIX face an increased risk of bleeding, and the likelihood of early development of progressive arthropathy, alongside higher treatment-related costs. Bypassing agents can be used to prevent and control bleeding, as well as the recently-licensed prophylaxis, emicizumab, but their efficacy is less predictable than that of factor replacement therapy. Antibody eradication, by way of immune tolerance induction (ITI), is still the preferred management strategy for treating patients with inhibitors. This approach is successful in most patients, but some are difficult to tolerize and/or are unresponsive to ITI, and they represent the most complicated patients to treat. However, there are limited clinical data and guidelines available to help guide physicians in formulating the next treatment steps in these patients. This review summarizes currently available treatment options for patients with inhibitors, focussing on ITI regimens and those ITI strategies that may be used in difficult-to-treat patients. Some alternative, non-ITI approaches for inhibitor management are also proposed. This article is protected by copyright. All rights reserved.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
Publikations- och innehållstyp
- for (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ljung, Rolf
-
Auerswald, Guent ...
-
Benson, Gary
-
Dolan, Gerry
-
Duffy, Anne
-
Hermans, Cedric
-
visa fler...
-
Jiménez-Yuste, V ...
-
Lambert, Thierry
-
Morfini, Massimo
-
Zupančić-Šalek, ...
-
Santagostino, El ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Lunds universitet